Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2016 Aug 5;15(10):2521–2529. doi: 10.1158/1535-7163.MCT-16-0258

Figure 5.

Figure 5

Ponatinib treatment results in tumor regression. A, C/KR mice with MRI-detectable lung tumors were treated with vehicle (upper panel) or ponatinib (30 mg/kg/day, 5 days/week, p.o., lower panel) for 1 month and then analyzed by MRI again (n = 4 in each group). Lung tissue sections at the end point were stained with H&E. Representative images of MRI, H&E sections, and image from Genie® v1 histology pattern recognition software analysis (right) are shown. B, comparison of MRI-detectable lung tumor burden prior to and post vehicle or ponatinib treatment. Each line represents an individual mouse. Blue, vehicle-treated; Black, ponatinib-treated. C, lung tumor burden analyzed from samples of H&E stained lung tissue sections. V, vehicle-treated; P, ponatinib-treated. D, comparison of pRET, RET and β-actin proteins in the lungs of CCSP and C/KR mice treated with vehicle or ponatinib. CCSP, negative control mouse.

HHS Vulnerability Disclosure